Essential components of an effective transition from paediatric to adult neurologist care for adolescents with Duchenne muscular dystrophy; a consensus derived using the Delphi methodology in Eastern Europe, Greece and Israel.
Adolescents
DMD
Delphi
Duchenne muscular dystrophy
Life expectancy
Transition
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
received:
25
10
2023
accepted:
01
07
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
9
7
2024
Statut:
epublish
Résumé
An increasing number of patients with Duchenne muscular dystrophy (DMD) now have access to improved standard of care and disease modifying treatments, which improve the clinical course of DMD and extend life expectancy beyond 30 years of age. A key issue for adolescent DMD patients is the transition from paediatric- to adult-oriented healthcare. Adolescents and adults with DMD have unique but highly complex healthcare needs associated with long-term steroid use, orthopaedic, respiratory, cardiac, psychological, and gastrointestinal problems meaning that a comprehensive transition process is required. A sub-optimal transition into adult care can have disruptive and deleterious consequences for a patient's long-term care. This paper details the results of a consensus amongst clinicians on transitioning adolescent DMD patients from paediatric to adult neurologists that can act as a guide to best practice to ensure patients have continuous comprehensive care at every stage of their journey. The consensus was derived using the Delphi methodology. Fifty-three statements were developed by a Steering Group (the authors of this paper) covering seven topics: Define the goals of transition, Preparing the patient, carers/parents and the adult centre, The transition process at the paediatric centre, The multidisciplinary transition summary - Principles, The multidisciplinary transition summary - Content, First visit in the adult centre, Evaluation of transition. The statements were shared with paediatric and adult neurologists across Central Eastern Europe (CEE) as a survey requesting their level of agreement with each statement. Data from 60 responders (54 full responses and six partial responses) were included in the data set analysis. A consensus was agreed across 100% of the statements. It is hoped that the findings of this survey which sets out agreed best practice statements, and the transfer template documents developed, will be widely used and so facilitate an effective transition from paediatric to adult care for adolescents with DMD.
Identifiants
pubmed: 38982500
doi: 10.1186/s13023-024-03270-2
pii: 10.1186/s13023-024-03270-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
260Informations de copyright
© 2024. The Author(s).
Références
Blake DJ, Weir A, Newey SE, Davies. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291–329.
doi: 10.1152/physrev.00028.2001
pubmed: 11917091
Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5(8):872–6.
doi: 10.1038/sj.embor.7400221
pubmed: 15470384
pmcid: 1299132
Sarkozy A, et al. 263rd ENMC International Workshop: Focus on female carriers of dystrophinopathy: refining recommendations for prevention, diagnosis, surveillance, and treatment. Neuromuscul Disord. 2023;33(3):274–84.
doi: 10.1016/j.nmd.2023.01.003
pubmed: 36804616
Hoffman EP, Bronson A, Levin AA, et al. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle. Am J Pathol. 2011;179(1):12–22.
doi: 10.1016/j.ajpath.2011.03.050
pubmed: 21703390
pmcid: 3124804
Ciafaloni E, Moxley RT. Treatment options for Duchenne muscular dystrophy. Curr Treat Options Neurol. 2008;10(2):86–93.
doi: 10.1007/s11940-008-0010-4
pubmed: 18334131
Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, STARnet MD. Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation. J Child Neurol. 2015;30:1275–80.
doi: 10.1177/0883073814558120
pubmed: 25414237
Matthews_E, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2016;5:CD003725. https://doi.org/10.1002/14651858.CD003725.pub4 .
Landfeldt E, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35:643–53.
doi: 10.1007/s10654-020-00613-8
pubmed: 32107739
pmcid: 7387367
Deng J, Zhang J, Shi K, Liu Z. Drug development progress in duchenne muscular dystrophy. Front Pharmacol. 2022;13:950651. https://doi.org/10.3389/fphar.2022.950651 .
doi: 10.3389/fphar.2022.950651
pubmed: 35935842
pmcid: 9353054
Angulski B, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023;14:1183101. https://doi.org/10.3389/fphys.2023.1183101 .
doi: 10.3389/fphys.2023.1183101
Trout CJ, et al. A Transition Toolkit for Duchenne Muscular Dystrophy. Pediatrics. 2018;142(Suppl 2):S110–7.
doi: 10.1542/peds.2018-0333M
pubmed: 30275255
Birnkrandt DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17(5):445–55.
doi: 10.1016/S1474-4422(18)30026-7
Wasilewska E, et al. Transition from Childhood to Adulthood in Patients with Duchenne Muscular Dystrophy. Medicina. 2020;56:426. https://doi.org/10.3390/medicina56090426 .
doi: 10.3390/medicina56090426
pubmed: 32846887
pmcid: 7557675
Jarvis SW, et al. Transition of children with life-limiting conditions to adult care and healthcare use: a systematic review. Pediatr Res. 2021;90:1120–31.
doi: 10.1038/s41390-021-01396-8
pubmed: 33654285
pmcid: 8671088
Molnár MJ, Sági JCS, Szabó L, Grosz Z. The transition of children with rare diseases from pediatric to adult care. Orv Hetil. 2022;163(51):2021–6.
doi: 10.1556/650.2022.32660
pubmed: 36528825